Go Pro
→ A Dark Day Is Coming to America (From TradeSmith) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Biofrontera Inc. stock logo
BFRIW
Biofrontera
$0.03
+0.3%		$0.03
$0.02
▼
$0.15
N/AN/A6,231 shs804 shs
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
$0.00
$0.00
▼
$0.00
N/A-1.23736 shs1 shs
CINGW
Cingulate
$0.01
+26.9%		$0.02
$0.00
▼
$0.12
N/AN/A35,055 shs35,562 shs
60 Degrees Pharmaceuticals, Inc. stock logo
SXTPW
60 Degrees Pharmaceuticals
$0.04
$0.03
$0.02
▼
$0.15
N/AN/A10,211 shs408 shs
7 Stocks That Will Be Magnificent in 2026 Cover
7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Biofrontera Inc. stock logo
BFRIW
Biofrontera
+0.34%+26.18%+45.54%-3.29%-75.90%
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
0.00%0.00%0.00%-80.00%-50.00%
CINGW
Cingulate
+26.88%+45.68%-44.34%-56.30%-76.40%
60 Degrees Pharmaceuticals, Inc. stock logo
SXTPW
60 Degrees Pharmaceuticals
0.00%+18.00%+22.07%-11.50%-67.73%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Biofrontera Inc. stock logo
BFRIW
Biofrontera
$0.03
+0.3%		$0.03
$0.02
▼
$0.15
N/AN/A6,231 shs804 shs
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
$0.00
$0.00
▼
$0.00
N/A-1.23736 shs1 shs
CINGW
Cingulate
$0.01
+26.9%		$0.02
$0.00
▼
$0.12
N/AN/A35,055 shs35,562 shs
60 Degrees Pharmaceuticals, Inc. stock logo
SXTPW
60 Degrees Pharmaceuticals
$0.04
$0.03
$0.02
▼
$0.15
N/AN/A10,211 shs408 shs
7 Stocks That Will Be Magnificent in 2026 Cover
7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Biofrontera Inc. stock logo
BFRIW
Biofrontera
+0.34%+26.18%+45.54%-3.29%-75.90%
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
0.00%0.00%0.00%-80.00%-50.00%
CINGW
Cingulate
+26.88%+45.68%-44.34%-56.30%-76.40%
60 Degrees Pharmaceuticals, Inc. stock logo
SXTPW
60 Degrees Pharmaceuticals
0.00%+18.00%+22.07%-11.50%-67.73%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Biofrontera Inc. stock logo
BFRIW
Biofrontera
0.00
N/AN/AN/A
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
0.00
N/AN/AN/A
CINGW
Cingulate
0.00
N/AN/AN/A
60 Degrees Pharmaceuticals, Inc. stock logo
SXTPW
60 Degrees Pharmaceuticals
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Biofrontera Inc. stock logo
BFRIW
Biofrontera
$43.20MN/AN/AN/AN/AN/A
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
N/AN/AN/AN/AN/AN/A
CINGW
Cingulate
N/AN/AN/AN/AN/AN/A
60 Degrees Pharmaceuticals, Inc. stock logo
SXTPW
60 Degrees Pharmaceuticals
$1.00MN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Biofrontera Inc. stock logo
BFRIW
Biofrontera
N/AN/AN/AN/AN/AN/AN/AN/AN/A
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
-$39.65MN/AN/AN/AN/AN/AN/AN/AN/A
CINGW
Cingulate
N/AN/AN/AN/AN/AN/AN/AN/AN/A
60 Degrees Pharmaceuticals, Inc. stock logo
SXTPW
60 Degrees Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Biofrontera Inc. stock logo
BFRIW
Biofrontera
N/AN/AN/AN/AN/A
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
N/AN/AN/AN/AN/A
CINGW
Cingulate
N/AN/AN/AN/AN/A
60 Degrees Pharmaceuticals, Inc. stock logo
SXTPW
60 Degrees Pharmaceuticals
N/AN/AN/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Biofrontera Inc. stock logo
BFRIW
Biofrontera
N/A
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
N/A
CINGW
Cingulate
N/A
60 Degrees Pharmaceuticals, Inc. stock logo
SXTPW
60 Degrees Pharmaceuticals
N/A

Insider Ownership

CompanyInsider Ownership
Biofrontera Inc. stock logo
BFRIW
Biofrontera
N/A
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
6.60%
CINGW
Cingulate
N/A
60 Degrees Pharmaceuticals, Inc. stock logo
SXTPW
60 Degrees Pharmaceuticals
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Biofrontera Inc. stock logo
BFRIW
Biofrontera
70N/AN/ANot Optionable
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
603.86 million4.55 millionNot Optionable
CINGW
Cingulate
20N/AN/ANot Optionable
60 Degrees Pharmaceuticals, Inc. stock logo
SXTPW
60 Degrees Pharmaceuticals
2N/AN/ANot Optionable

Recent News About These Companies

60 Degrees Pharmaceuticals Reports Second Quarter 2026 Financial Results with 106% Increase in Net Product Revenues
August 14, 2026  |  quiverquant.comQ
60 Degrees Pharmaceuticals Shareholders Approve Key Governance Actions
August 6, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/60-degrees-pharmaceuticals-shareholders-approve-key-governance-actions?utm_source=marketbeat.com&utm_medium=referral
60 Degrees Pharmaceuticals Completes Private Placement to Raise Capital
August 4, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/60-degrees-pharmaceuticals-completes-private-placement-to-raise-capital?utm_source=marketbeat.com&utm_medium=referral
60 Degrees Pharmaceuticals Announces $1.0 Million Private Placement of Common Stock and Warrants
July 30, 2026  |  quiverquant.comQ
60 Degrees updates strategy for ARAKODA and profitability
July 20, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/60-degrees-updates-strategy-for-arakoda-and-profitability?utm_source=marketbeat.com&utm_medium=referral
Interim Trial Plan Finalized for Tafenoquine Babesiosis Study
July 9, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/interim-trial-plan-finalized-for-tafenoquine-babesiosis-study?utm_source=marketbeat.com&utm_medium=referral
60 Degrees details tafenoquine priority review voucher strategy
June 3, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/60-degrees-details-tafenoquine-priority-review-voucher-strategy?utm_source=marketbeat.com&utm_medium=referral
60 Degrees Pharmaceuticals, Inc. Partners with Runway Health to Offer ARAKODA® for Convenient Online Malaria Prevention
April 15, 2026  |  quiverquant.comQ
60 Degrees Pharmaceuticals Reports 65% Increase in FY 2025 Net Product Revenues to $1.0 Million and Operational Developments
March 31, 2026  |  quiverquant.comQ
60 Degrees Updates Affiliate Share Ownership Disclosure Error
March 20, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/60-degrees-updates-affiliate-share-ownership-disclosure-error?utm_source=marketbeat.com&utm_medium=referral
60 Degrees Pharmaceuticals Updates Legal Opinion for ATM Offering
March 13, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/60-degrees-pharmaceuticals-updates-legal-opinion-for-atm-offering?utm_source=marketbeat.com&utm_medium=referral
60 Degrees Pharmaceuticals Regains Nasdaq Listing Compliance Status
February 12, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/60-degrees-pharmaceuticals-regains-nasdaq-listing-compliance-status?utm_source=marketbeat.com&utm_medium=referral
GoodRx Partners with 60 Degrees Pharmaceuticals to Offer Up to 30% Savings on ARAKODA® for Malaria Prevention
February 2, 2026  |  quiverquant.comQ
60 Degrees Pharmaceuticals Faces Immediate Nasdaq Delisting Appeal
January 23, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/60-degrees-pharmaceuticals-faces-immediate-nasdaq-delisting-appeal?utm_source=marketbeat.com&utm_medium=referral
60 Degrees Pharmaceuticals Implements One-for-Four Reverse Split
January 21, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/60-degrees-pharmaceuticals-implements-one-for-four-reverse-split?utm_source=marketbeat.com&utm_medium=referral
60 Degrees Pharma outlines growth strategy in investor webinar
January 8, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/60-degrees-pharma-outlines-growth-strategy-in-investor-webinar?utm_source=marketbeat.com&utm_medium=referral
60 Degrees Pharmaceuticals, Inc. Confirms Continuation of B-FREE Study to Assess ARAKODA® for Chronic Babesiosis Treatment
December 29, 2025  |  quiverquant.comQ
60 Degrees Pharmaceuticals Plans Expansion of Sales and Marketing Initiatives Following Positive Clinical Pilot Results
December 11, 2025  |  quiverquant.comQ
60 Degrees Pharmaceuticals Launches First-Ever Study for Tafenoquine in Chronic Babesiosis Patients
November 21, 2025  |  quiverquant.comQ
60 Degrees Pharmaceuticals Faces Financial Challenges Amid Growth Efforts
November 17, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/60-degrees-pharmaceuticals-faces-financial-challenges-amid-growth-efforts?utm_source=marketbeat.com&utm_medium=referral

Media Sentiment Over Time

Biofrontera stock logo

Biofrontera NASDAQ:BFRIW

$0.03 +0.00 (+0.34%)
As of 08/19/2026 10:08 AM Eastern

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

Calithera Biosciences stock logo

Calithera Biosciences NASDAQ:CALA

Calithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.

Cingulate NASDAQ:CINGW

$0.01 +0.00 (+26.88%)
Closing price 08/19/2026 03:49 PM Eastern
Extended Trading
$0.01 +0.00 (+7.63%)
As of 08/19/2026 06:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

60 Degrees Pharmaceuticals stock logo

60 Degrees Pharmaceuticals NASDAQ:SXTPW

$0.04 0.00 (0.00%)
As of 08/18/2026 01:49 PM Eastern

60 Degrees Pharmaceuticals, Inc. operates as a specialty pharmaceutical company that engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19; Tafenoquine for fungal lung infections, tick-borne diseases, candidiasis, and other infectious and non-infectious diseases; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is based in Washington, District of Columbia.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas